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In vivo bioluminescent imaging (BLI) permits the visualization of engineered biolu-
minescence from living cells and tissues to provide a unique perspective toward the 
understanding of biological processes as they occur within the framework of an authen-
tic in  vivo environment. The toolbox of in  vivo BLI includes an inventory of luciferase 
compounds capable of generating bioluminescent light signals along with sophisticated 
and powerful instrumentation designed to detect and quantify these light signals 
non-invasively as they emit from the living subject. The information acquired reveals the 
dynamics of a wide range of biological functions that play key roles in the physiological 
and pathological control of disease and its therapeutic management. This mini review 
provides an overview of the tools and applications central to the evolution of in vivo BLI 
as a core technology in the preclinical imaging disciplines.
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inTRODUCTiOn
In vivo bioluminescent imaging (BLI) enables the visualization of biological processes as they occur 
within the living subject. The information obtained is unprecedented in its ability to elucidate 
biology beyond the boundaries of the conventional in vitro assay, where the complex interactions 
of a living system are all but ignored. In vivo BLI uses the luciferase family of proteins to create 
signature bioluminescent outputs that are then externally captured by advanced cameras (Figure 1). 
Luciferases operate in tandem with their luciferin substrates to generate light via an oxidation 
decarboxylation reaction that forms an excited state intermediate that releases energy in the form 
of photons as it returns to its ground state. In nature, bioluminescence is generated by various 
bacteria, fungi, protozoa, dinoflagellates, and higher-order terrestrial and marine organisms, with 
the firefly being the most recognized example. Molecular biology has enabled the genes involved 
in bioluminescent light reactions to be isolated, manipulated, and reapplied toward applications, 
such as in vivo BLI, where bioluminescence as an optical emission signature exhibits certain unique 
imaging advantages. Among the most critical is a superior signal-to-noise ratio due to cells and 
tissues emitting virtually no intrinsic bioluminescence, thus effectively eliminating background 
interference when probing for a bioluminescent signal within the intricate milieu of a living entity. 
However, detecting bioluminescence at depths beyond a few centimeters inside of a living animal 
remains challenging because light signals must be obtained and evaluated after passing through 
host tissue that absorbs, attenuates, and scatters their emissions (1). This has currently constrained 
in  vivo BLI to small animal models, such as mice and rats, with service primarily limited to 
FiGURe 1 | In vivo BLi uses advanced camera imaging systems to visualize live animal subjects as they express bioluminescence from targeted 
cells and tissues, thereby allowing fundamental biological processes to be monitored non-invasively. Advances in the in vivo BLI field have created 
luciferase proteins with expanded wavelength emission profiles, stronger and more stable signal generation, substrate-independent real-time expression, and 
proximity-based expression characteristics that are providing innovative tools for preclinical diagnostics, drug discovery, and toxicology research.
2
Xu et al. In Vivo Bioluminescent Imaging Methods
Frontiers in Oncology | www.frontiersin.org June 2016 | Volume 6 | Article 150
preclinical imaging applications. This mini review provides an 
overview of the luciferases currently being applied in in  vivo 
imaging applications along with the toolbox of approaches that 
continue to expand the capabilities of in vivo BLI.
LUCiFeRASeS FOR BLi APPLiCATiOnS
Luciferases applied in in  vivo BLI include those derived from 
beetles, bacteria, and various marine species (Table 1), with the 
firefly luciferase (FLuc) being the most widely used. FLuc requires 
d-luciferin (a heterocyclic carboxylic acid), ATP, and molecular 
oxygen for light production. At a pH between 7.5 and 8.5, FLuc 
catalyzes the reaction between d-luciferin and ATP to form 
luciferyl-adenylate, which in the presence of oxygen then under-
goes an oxidative decarboxylation reaction to form CO2, AMP, 
and oxyluciferin. Initially formed as an excited state intermedi-
ate, oxyluciferin quickly returns to its ground state and releases 
energy in the form of light (2). In addition to FLuc, other beetle 
luciferases, such as the green (CBG) and red (CBR) click beetle 
luciferases, emerald luciferase (ELuc), and stable red luciferase 
(SRL), also utilize d-luciferin as their substrate. However, despite 
this common substrate, these luciferases emit light of different 
wavelengths (Table 1).
Within the bacterial genera, bioluminescence from Photo­
bacterium and Aliivibrio/Vibrio are typically applied. These 
systems encode the lux gene cassette, which includes the 
luxAB genes encoding a heterodimeric bacterial luciferase and 
the luxCDE genes encoding a fatty acid synthetase/reductase 
complex that generates a long-chain fatty aldehyde substrate 
from endogenous intracellular metabolites. Marine biolumines-
cent bacteria also possess a luxG/frp gene that encodes a flavin 
reductase that recycles reduced flavin mononucleotide (FMNH2) 
for the luciferase reaction. Similar to beetle luciferases, bacterial 
luciferase generates light in an ATP-dependent manner in the 
presence of long-chain aldehyde, FMNH2, and molecular oxygen 
(33). Distinctive to bacterial bioluminescence is the ability of 
cells expressing the full luxCDABE gene cassette to produce 
light autonomously without the need for exogenous luciferin 
by self-supplying the aldehyde and FMNH2 substrates. While 
bacterial bioluminescence is traditionally employed to label 
bacterial pathogens for in vivo real-time infection tracking due 
to its prokaryotic origin, the lux cassette has been syntheti-
cally optimized for autonomous bioluminescent expression in 
eukaryotic organisms, allowing substrate-free in  vivo imaging 
of mammalian cells (18).
The remaining luciferases include those isolated from marine 
invertebrates. Unlike other luciferases, marine luciferases utilize 
their luciferin substrate and molecular oxygen to generate light 
in an ATP-independent fashion. There is also no common 
luciferin substrate for all marine luciferases. While Gaussia 
(GLuc), Renilla (RLuc), and Metridia (MLuc) luciferases share 
the same substrate coelenterazine, Cypridina (CLuc) and Vargula 
(VLuc) luciferases catalyze their reactions using cypridina and 
vargulin, respectively. Some marine luciferases, including GLuc 
and MLuc, are naturally secreted outside of the cell, thus allowing 
bioluminescent detection without cell lysis (25, 27).
TABLe 1 | The inventory of luciferases for in vivo BLi applications.
Luciferase Luciferin substrate Peak emission  
(nm) (25°C)
Reference examples of in vivo BLi applications
Beetle luciferases
Photinus pyralis (firefly; FLuc, ffluc, or luc) and 
its enhanced variants (effLuc, luc2)
d-luciferin 560 (3–5) •	 Detection of cancer cells and evaluation of 
tumor treatment (3, 5)
•	 Imaging of neural precursor cell migration to 
glioma tumor (6)
•	 Imaging of T cell migration to tumors (7)
•	 Split luciferase assay to image apoptosis in 
response to chemotherapy and radiotherapy 
in a glioma model (8)
Red-shifted firefly luciferase PRE9 d-luciferin 620 (9)
Pyrearinus termitilluminans (click beetle 
emerald; ELuc)
d-luciferin 538 (10)
Pyrophorus plagiophthalamus (click beetle red; 
CBR)
d-luciferin 615 (11)
Pyrophorus plagiophthalamus (click beetle 
green; CBG)
d-luciferin 540 (12)
Phrixothrix hirtus (railroad worm stable 
luciferase red; SLR)
d-luciferin 630 (13)
Bacterial luciferases
Aliivibrio fischeri, Vibrio harveyi, and Photorhabdus 
luminescens lux for bacterial expression
FMNH2 + long-chain 
aliphatic aldehyde
490 (14, 15) •	 Simultaneous imaging of lux-labeled bacterial 
trafficking to FLuc-tagged tumor (14)
•	 Substrate-free imaging of human  
cells in vivo (16)
•	 Substrate-free real-time imaging of bacterial 
infection of human cells (17)
Synthetic lux for mammalian expression FMNH2 + long-chain 
aliphatic aldehyde  
(self-supplied by 
luxCDEfrp)
490 (18, 19)
Marine luciferases
Renilla reniformis (RLuc) and its enhanced variants 
(RLuc8 and RLuc8.6–535)
Coelenterazine 482–535 (20–22) •	 RLuc multiplexed with FLuc to monitor tumor 
regression in response to therapeutic genes 
delivery by neural precursor cells (6)
•	 VLuc multiplexed with FLuc and RLuc to 
track delivery of therapeutic genes into brain 
tumor (23)
•	 BRET assay to detect tumor metastasis (24)
Gaussia princeps (GLuc) and its mutants (I90L, 
8990, 90115, Monsta, etc.)
Coelenterazine 482–503 (25, 26)
Metridia longa (MLuc7, MLuc164) Coelenterazine 486–498 (27, 28)
Aequorea victoria (aequorin) Coelenterazine 470 (29)
Vargula hilgendorfii (VLuc) Vargulin 462 (30)
Cypridina noctiluca (CLuc) Cypridina 460 (31)
Oplophorus gracilirostris (NanoLuc) Furimazine 460 (32)
Benthosema pterotum (BP) Coelenterazine 475 (7)
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THe TOOLBOX OF BLi APPROACHeS
Mutated and Synthetic Luciferase
The high utility and common limitations shared by luciferases has 
made them especially attractive targets for synthetic modifica-
tion. One of the first major synthetic luciferase modifications 
was a polymutated variant of RLuc, which incorporated eight 
independent single amino acid changes to increase protein stabil-
ity and improve light output (20). This mutated variant allowed 
for improved function during serum exposure in small animals, 
provided a facile means for conjugating luciferase protein to 
various ligands (34), and has recently been used for conjugation 
to immunoglobulin G proteins for visualizing antigen–antibody 
reactions (35).
Perhaps the most valuable synthetic luciferase modifications 
for in vivo BLI have been those that shift the luciferases’ emission 
signal further into the red spectrum, thereby improving signal 
penetration through living tissue. To overcome the naturally 
blue-shifted emission wavelength of RLuc, Loening et  al. (21) 
generated a library of active site mutations and identified multiple 
variants with emission spectra peaks ranging from 475 to 547 nm. 
Branchini et al. (36) employed a similar approach with FLuc that 
shifted its native 557 nm emission peak to 617 nm.
Leveraging the proteomic sequences of known luciferases, 
Kim  and Izumi (37) applied a consensus sequence-driven 
mutage nesis strategy to identify amino acids common to 
copepod luciferases and arranged these sequences under the 
constraints suggested by a statistical coupling analysis (38) to 
mimic the natural evolutionary constraints of the proteins. 
Using this strategy, they designed artificial luciferases (ALucs) 
that retained favorable emission wavelengths in the 515–548 nm 
range. This strategy enables the synthetic generation of alternative 
classes of luciferases for the continued expansion of BLI beyond 
those found in nature.
Synthetic Luciferin Analogs
For in vivo BLI to occur under the majority of luciferase/luciferin 
combinations, the luciferin substrate must first be injected into 
the animal and then diffuse to where the luciferase-expressing 
cells are located. This series of events can be challenging. The 
biodistribution of luciferin substrates in small animals is not 
homogenous, individual eukaryotic cells are limited in their 
ability to freely take up substrate, and the mere presence of the 
luciferin substrate represents a chemical contaminant that may 
unknowingly introduce experimental artifacts and/or toxicologi-
cal side effects. Synthetic luciferins with properties better tuned 
4Xu et al. In Vivo Bioluminescent Imaging Methods
Frontiers in Oncology | www.frontiersin.org June 2016 | Volume 6 | Article 150
to the in vivo environment are being developed to address some 
of these problems. Craig et  al. (39) created some of the early 
chemically modified (esterified) d-luciferin analogs designed for 
improved cellular uptake kinetics and consequent near sixfold 
increases in bioluminescence output. However, for in  vivo 
imaging, the focus has transitioned to red-shifting the emission 
wavelength for improved tissue penetration. This has resulted 
in aminoluciferin analogs, such as cyclic aminoluciferins and 
seleno-d-aminoluciferins, with wavelength emissions around 
600 nm (40). Unfortunately, the majority of these analogs yield 
lower light intensities than conventional luciferin, although the 
CycLuc1 substrate reported by Evans et al. (41) does demonstrate 
superior photon flux under non-saturating substrate condi-
tions. Infra-luciferin (λmax  =  706  nm), a π-conjugated analog 
(λmax = 675 nm), and CycLuc10 (λmax = 648 nm) have successfully 
shifted their wavelengths even further into the far-red regions 
(42–44). However, maintaining elevated photon yields remains 
challenging, although the increased efficiency of signal penetra-
tion at these longer wavelengths does offer heightened resolution.
Multiplexed BLi
In multiplexed BLI, the subject is tagged with multiple luciferases 
that utilize different substrates, which are injected sequentially 
to trigger each bioluminescent signal to enable simultaneous 
monitoring of multiple biological processes. Common luciferase 
combinations include d-luciferin-activated beetle luciferase and 
coelenterazine-activated marine luciferase. The selectivity and 
specificity of luciferin substrates ensures minimal cross talk. 
This approach has been applied to monitor gene expression and 
promoter activities (45), mesenchymal stem cell differentiation 
(46), and cell migration and tumor apoptosis (6, 47). A triple 
BLI system consisting of the FLuc/d-luciferin, GLuc/coelen-
terazine, and VLuc/vargulin pairs has also been reported for 
simultaneous monitoring of three distinct biological events in 
an orthotopic brain tumor model (23). However, using multiple 
substrates inevitably introduces biases due to differential sub-
strate biodistribution and uptake in animal tissues. Meanwhile, 
multiple substrate injections can be stressful for the animal and 
introduce potential operational errors. These drawbacks can be 
alleviated by utilizing a single substrate to simultaneously initiate 
multiple luciferases that emit light of separable colors. A com-
mon approach is to employ one luciferase with a green emission 
spectrum and a second luciferase emitting a more red-shifted 
wavelength. Upon a single-substrate application, both luciferases 
are activated, and the resulting green and red light signal can be 
spectrally resolved using appropriate detection systems. Beetle 
luciferases activated by d-luciferin, including FLuc, CBG, and 
CBR, are currently the most common reporters used for single-
substrate multicolor BLI applications (13, 48–51). However, for 
in vivo applications, this arrangement is still constrained due to 
increased absorption and attenuation of the shorter wavelength 
(green) light compared to that of the red-shifted signal in animal 
tissues, which introduces potential detection biases.
Split Luciferases
Split luciferases, or luciferase fragments, are unique tools for 
probing protein–protein interactions. Instead of using the 
complete enzyme, the luciferase protein is split into a C-terminus 
fragment and an N-terminus fragment that are not capable of 
catalyzing the bioluminescent reaction on their own. In split 
luciferase complementation assays, each luciferase fragment is 
attached to each partner of the interacting peptides, domains, 
and/or full proteins. Upon interaction of the proteins of interest, 
the luciferase fragments are brought to a close proximity to form 
a complete and functional enzyme that produces bioluminescence 
when a luciferin substrate is available (52). Luciferase fragment 
complementation imaging can be designed to directly identify 
interacting protein pairs (53) and to indirectly report protein–
protein interactions induced by various biological processes, such 
as binding of intracellular messengers (e.g., cyclic AMP and Ca2+) 
(54, 55), protein kinase activities (56, 57), caspase-3-mediated 
apoptosis (8), and activation and/or inhibition of disease-related 
cell signaling pathways (58, 59). Multiple luciferases can also be 
used for multiplexed examination of complex interactions involv-
ing multiple protein partners simultaneously in the same subject 
(12, 60). For improved in vivo applications, novel split sites and 
modifications of the luciferase enzyme are being continuously 
identified to enhance their characteristics (i.e., decreased basal 
activity, increased specificity, improved signal-to-noise ratio) (61).
Caged Luciferin
The caged luciferin reporter system uses a luciferin substrate 
that has been modified such that it cannot interact with its 
complementary luciferase to generate bioluminescence until an 
enzymatic cleavage event occurs (62). Lugal (d-luciferin-O-β-
galactoside) is one example of a caged luciferin that only actively 
interacts with FLuc upon removal of its galactoside moiety by 
β-galactosidase. Thus, the bioluminescent reporter cell remains 
“dark” even after the addition of the Lugal substrate, with the co-
addition of β-galactosidase being required to ultimately initiate 
light emission. Using this strategy, one cell (the reporter cell) can 
be designed to express FLuc, while another cell (the activator cell) 
expresses β-galactosidase. If the two cells are in close proximity, 
then the β-galactosidase released from the activator cell cleaves 
the Lugal to initiate light emission from the reporter cell. As the 
distance between these two cells increases, the intensity of the 
light response correspondingly decreases. For example, this has 
enabled in vivo bioluminescent visualization of tumor metastasis 
in mouse models, where β-galactosidase-expressing hematopoi-
etic cells distributed throughout a mouse functionally activated 
luciferase-expressing breast cancer cells that had metastasized 
from a tumor implant (63). Due to Lugal being somewhat 
non-selective under biological conditions, other caged luciferin 
substrates have been developed that operate under a number of 
more selective enzymatic reaction schemes (β-lactamase, alkaline 
phosphatase, nitroreductase) (64, 65).
Bioluminescence Resonance 
energy Transfer
Bioluminescence resonance energy transfer (BRET) pairs 
together two chromophores such that the emission spectra of one 
(the bioluminescent donor) activates the excitation spectra of the 
other (the fluorescent acceptor) (66). In its earliest configuration, 
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it exploited the 482-nm bioluminescent emission of Renilla lucif-
erase to activate an enhanced yellow fluorescent protein (EYFP), 
thereby “switching” the blue-green color of RLuc to a 527-nm 
yellow emission (67). The switching only occurs if the donor and 
recipient chromophores are properly oriented and situated in 
close proximity (≤10 nm apart), which enables BRET’s primary 
application as an indicator of protein–protein interactions via 
the attachment of the donor chromophore to one protein and 
the recipient chromophore to the other protein (68). BRET has 
since evolved to include other bioluminescent/fluorescent pair-
ings, which, for in  vivo applications, have centered on shifting 
the emission spectra more toward the red to far-red regions to 
improve tissue penetration (24, 69–71). BRET has also advanced 
beyond fluorescent proteins to include organic dye (72) and 
quantum dot conjugates (73).
Fluorescence by Unbound excitation 
from Luminescence
Fluorescence by unbound excitation from luminescence (FUEL) 
is similar to BRET in that it uses the emission spectra of a bio-
luminescent donor to activate the excitation spectra of a fluores-
cent acceptor. However, whereas BRET requires the donor and 
acceptor to reside within an approximate 10 nm distance of each 
other, FUEL can theoretically occur at donor/acceptor distances 
separated by micrometers to centimeters (74, 75). FUEL takes 
advantage of the unfocused radiative dissemination of photons 
by luciferase-bearing entities to activate neighboring fluorescent 
light sources. In one of its earliest demonstrations, Escherichia 
coli cells expressing bacterial luciferase were placed in one quartz 
cuvette, while red-emitting quantum dots (QD705, Invitrogen) 
with overlapping excitation wavelengths were placed in a neigh-
boring cuvette. Photons emitted by E. coli were shown to activate 
red-shifted fluorescence from QD705, with signal intensity being 
dependent on the distance separating the two cuvettes. Injection 
of bioluminescent bacteria and QD705 into mice showed similar 
activation of red fluorescence emission under in vivo BLI. FUEL 
may serve as a unique mechanism to gage coproximity of donors 
and acceptors, much like BRET, but across larger spans of space, 
for example, to discern interactions between tissues and organs 
separated on a mesoscopic scale.
Bioluminescence Assisted Switching 
and Fluorescence imaging
Bioluminescence assisted switching and fluorescence imaging 
(BASFI) is another spin-off of BRET, wherein a bioluminescent 
donor activates a reversible photoswitchable fluorescent accep-
tor protein. Proof of concept for BASFI has been demonstrated 
using the pairing of the bioluminescent Rluc8 donor with the 
photoswitchable fluorescent protein DG1 acceptor (76). DG1 
normally exists in its excited state, emitting green fluorescence at 
450–550 nm, but can be switched to an off-state when exposed 
to wavelengths around 488 nm. A DG1–Rluc8 fusion construct 
was transfected into a human embryonic kidney cell, thereby 
endowing it with a green fluorescent phenotype. Exposing the 
cell to a 488 nm laser switched DG1 to its off-state, and the cell 
became “dark.” Addition of a coelenterazine methoxy substrate 
then activated Rluc8, whose 400  nm emission switched DG1 
back to its on-state. In traditional BRET, this on-state is transient 
and short-lived. In BASFI, this on-state persists for as long as 
the donor bioluminescence is being provided, thereby enabling 
the accumulation of signal over time. This allows supply of the 
activation signal to be decoupled from measurement of the 
emission signal to potentially reduce background and increase 
sensitivity. BASFI still requires close association between the 
donor and acceptor (≤10 nm), so its primary application remains 
with studying protein–protein interactions.
Bioluminescent enzyme-induced 
electron Transfer
The bioluminescent enzyme-induced electron transfer (BioLeT) 
concept uses luciferin analogs that have been modified to 
contain moieties of differing electron donating capacities and 
then using the ensuing electron transfer process as an on/off 
switch to modulate bioluminescent signal output. In its proof-
of-concept format, aminoluciferin substrates were modified to 
contain benzene moieties of differing highest occupied molecular 
orbital (HOMO) energy levels (77, 78). Substrates containing 
benzene moieties with high HOMO energy levels, such as a 
diaminophenyl moiety, were shown to quench bioluminescence 
when added to a FLuc reaction, presumably due to the elec-
tron transfer process occurring much more rapidly than the 
light-emitting reaction. Substrates containing benzene moieties 
with low HOMO energy levels did not quench bioluminescent 
signal output. A diamino-phenylpropyl-aminoluciferin (DAL) 
substrate was ultimately developed as a BioLeT probe for the 
targeting of biological nitric oxide. Upon reaction with nitric 
oxide, the diaminophenyl moiety is converted into a benzotria-
zole moiety with a lower HOMO energy level, thus transitioning 
from minimal to a highly bioluminescent output in the presence 
of luciferase. The scheme was validated in  vivo in a transgenic 
FLuc rat model intraperitoneally injected with DAL substrate 
followed by injection of a NOC7 compound that spontaneously 
released nitric oxide under physiological conditions. Nitric oxide 
accumulation was detected via increased bioluminescence emis-
sion as the diaminophenyl to benzotriazole conversion occurred 
within the rat. It is anticipated that the BioLeT process can be 
designed to target other biomolecules, such as singlet oxygen and 
metal ions, to assist in the real-time, non-invasive surveillance 
of a subject’s physiological state.
COnCLUSiOn
The superior signal-to-noise ratio due to the absence of intrinsic 
bioluminescence background in cells and animal tissues has made 
BLI an attractive tool for investigating biological processes as they 
occur in real-time in living animals. The past two decades have 
witnessed not only a bloom in the discovery and engineering of 
luciferases with improved expression and performance in mam-
malian cells but also the emergence and expansion of innovative 
applications of such luciferase reporters for in  vivo imaging. 
Despite in vivo BLI currently being constrained to small animal 
models, it has increasingly become a promising tool in preclinical 
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biomedical research to investigate real-time biological events in 
complex biological systems, and it is reasonable to expect that 
in vivo BLI will continue to play a crucial role in basic research, 
drug development, disease diagnosis, therapy management, and 
many other biomedical research and applications.
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